Generic Daclatasvir - , Daklinza, Natdac, Hepcinat, Myhep, Sofovir

Generic Daklinza is an antiviral medicine that precludes hepatitis C virus (HCV) to spread out in your body. It is used to cure genotype 3 chronic hepatitis C in mature patients without cirrhosis. This medicine is taken with another antiviral drug named sofosbuvir.

Natdac® is an inhibitor of the viral (hepatitis C virus) protein NS5A, which is used in the replication of hepatitis C virus within the liver cells (hepatocytes) and, thus, prevents the virus from entering infected hepatocytes into the blood. Thanks to this action, it is possible to prevent the spread of the virus in the body. Natdac® (daсlatasvir) is a highly specific direct action agent against hepatitis C virus (HCV) and has no pronounced activity against other RNA and DNA containing viruses, including human immunodeficiency virus (HIV). Natdac®, as an inhibitor of the nonstructural protein 5A (NS5A), a multifunctional protein required for HCV replication, suppresses two stages of the life cycle of the virus-viral RNA replication and virion assembly.

Hepcinat® - contains Sofosbuvir 400mg, the newest drug developed by the Indian company Natco Pharma with the help of high-tech equipment, with all the necessary standards and requirements. The drug is used to treat chronic hepatitis C. Treatment with sofosbuvir is used in a complex with other antivirals during a 'without interferon therapy' in virtually all leading clinics around the world, since this drug, which has undergone a lot of clinical and laboratory studies, showed good results. The effectiveness of the new drug for different genotypes of the virus is 92-96%.

Myhep® - sofosbuvir 400mg - is used to treat chronic hepatitis C as a component of a combined antiviral therapy regimen in adult patients in combination with other medications. Myhep® is a direct-acting antiviral that inhibits the RNA-dependent NS5B polymerase of the hepatitis C virus, which is essential for viral replication. Myhep® is a drug manufactured by Mylan Pharmaceuticals, based in India. All the products of this company are produced on modern equipment of a large plant built according to all norms and regulations of the World Health Organization.

Sofovir® is an Indian registered licensed analog of Sovaldi (Sofosbuvir). It is an inhibitor of the NS5B polymerase of hepatitis C virus (HCV) that contains 400mg of the active substance Sofosbuvir. It is used to treat chronic hepatitis C as a component of a combined antiviral therapy regimen in adults. Sofovir® can be used by patients who have not been treated before or who have had unsuccessful experience in the treatment of hepatitis C. Good efficacy has been shown with concomitant serious liver pathologies like cirrhosis and HIV infection.